Key result
Blebbistatin improves human iPSC-CM morphology and automated patch-clamp sodium current recordings by preventing hypercontraction.
Why the study?
Application of automated patch-clamp platforms in iPSC-CM research has been limited by difficulty maintaining the quality of single cells during dissociation and recording.
Blebbistatin allows for high-throughput, automated patch-clamp modeling of cardiac channelopathies using human iPSC-CMs by preventing calcium paradox injury.
May enable high-throughput iPSC-CM channelopathy modeling; hypothesis-generating for drug safety applications pending validation.
Recently, there have been great advances in cardiovascular channelopathy modeling and drug safety pharmacology using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The automated patch-clamp (APC) technique overcomes the disadvantages of the manual patch-clamp (MPC) technique, which is labor intensive and gives low output. However, the application of the APC platform is still limited in iPSC-CM based research, due to the difficulty in maintaining the high quality of single iPSC-CMs during dissociation and recording. In this study, we improved the method for single iPSC-CM preparation by applying 2.5 μM blebbistatin (BB, an excitation-contraction coupling uncoupler) throughout APC procedures (dissociation, filtration, storage, and recording). Under non-BB buffered condition, iPSC-CMs in suspension showed a severe bleb-like morphology. However, BB-supplement led to significant improvements in morphology and I Na recording, and we even obtained several CMs that showed spontaneous action potentials with typical morphology. Furthermore, APC faithfully recapitulated the single-cell electrophysiological phenotypes of iPSC-CMs derived from Brugada syndrome patients, as detected with MPC. Our study indicates that APC is capable of replacing MPC in the modeling of cardiac channelopathies using human iPSC-CMs by providing high-quality data with higher throughput.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Brugada syndrome. Blebbistatin vs. Non-blebbistatin buffered condition was evaluated on Cell morphology and sodium current (INa) recording quality. Blebbistatin supplementation led to significant improvements in morphology and sodium current recording of human iPSC-CMs, protecting them from hypercontraction and facilitating automated patch-clamp electrophysiology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: